Evidence map›Paper›PMID 42577276›Full record

ArticleFrontiers in bioengineering and biotechnology2026

Impact of CPPs on primary human NK cell CQAs during cell expansion - an experimental study using design of experiments.

Gregor Mattert, Christiane Schaffer, Aleksander Szarzynski, Valentin von Werz, Oliver Spadiut, Ralf Pörtner, Werner Dammermann

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gregor Mattert *Center for Translational Medicine, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.
Christiane Schaffer *Institute of Bioprocess and Biosystems Engineering, Hamburg University of Technology, Hamburg, Germany.
Aleksander Szarzynski *Technische Universität Wien, Fakultät für Technische Chemie, Vienna, Austria.
Valentin von WerzTechnische Universität Wien, Fakultät für Technische Chemie, Vienna, Austria.
Oliver Spadiut *Technische Universität Wien, Fakultät für Technische Chemie, Vienna, Austria.
Ralf Pörtner *Institute of Bioprocess and Biosystems Engineering, Hamburg University of Technology, Hamburg, Germany.
Werner Dammermann *Center for Translational Medicine, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human natural killer (NK) cells represent a promising leukocyte population for use in immune cell therapies. Hematologic as well as solid tumors have been shown to respond to treatment with autologous or allogeneic NK cells. Providing NK cells in sufficient quantity and quality (i.e., efficacy, safety, identity, purity, and yield), remains a challenge. A deeper insight into the critical process parameters (CPP) and critical quality attributes (CQA) of primary NK cell culture is needed for the understanding and control of NK cell manufacturing. Due to the large number of potential CPP's, a design of experiments (DoE) approach was used for systematic planning and reduction of the number of experiments. Primary NK cells from two donors were cultivated under batch conditions and varying CPP's. A detailed analysis of the impact of the investigated CPP's was conducted, and the DoE based experimental setup allowed the interpretation of the influence of each selected process parameter as well as their combination on the relevant CQAs. Based on this data, a statistical model was formulated, which allows predictions of the maximal viable cell number. This approach allows for detailed insight into the CPP's and possible optimizations in the production of cell therapy products.

Indexed as

cytotoxicityDoEglucosemathematical modelNK cells

Identifiers

PMID42577276
PMCPMC13454036

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.